Ankyrin repeat and IBR domain-containing protein 1 (ANKIB1)

Ankyrin repeat and IBR domain-containing protein 1 (ANKIB1) is a member of the RBR (RING-between-RING) family of E3 ubiquitin ligases, specifically part of the Ariadne subfamily[4]. It encodes a cytoplasmic protein with predicted roles in ubiquitin-dependent catabolism, likely functioning as either a solo E3 ligase or as part of a complex mediating transfer of ubiquitin to protein substrates in the cell[2][4]. ANKIB1 is notable for producing circular RNA transcripts (circ-ANKIB1) implicated in regulatory functions, including negative regulation of Schwann cell proliferation and involvement in axon regeneration after nerve injury[1]. In cancer biology, circ-ANKIB1 acts as a competing endogenous RNA to sequester tumor-suppressive microRNAs, contributing to chemoresistance and proliferation in osteosarcoma[1]. Transcriptomic changes in ANKIB1 are linked with neurodegeneration (as a biomarker for Alzheimer’s disease) and its promoter methylation patterns suggest a role in infectious/immune response[1]. While ANKIB1 has broad relevance for signaling and regulatory functions, direct drug targeting is early-stage, with no clinical drugs currently documented to bind or modulate ANKIB1 specifically[4][1][2].

Other names

ANKIB1KIAA1386DKFZP434A0225Ankyrin repeat and IBR domain containing 1[1][2][3]

For drugs targeting this molecule (general for E3 ligases): modulation (inhibition or activation) of protein ubiquitination and subsequent proteasomal degradation of substrates[4]; Indirect modulation through microRNAs or circular RNA regulation